SCHEMBL503049

SCHEMBL503049

N[C@@H](Cc1ccnc2ccccc12)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.53
MAPT P10636 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MEN1 O00255 2/20 0.52
LMNA P02545 2/20 0.52
BLM P54132 2/20 0.52
PMP22 Q01453 2/20 0.52
KMT2A Q03164 2/20 0.52
HIF1A Q16665 2/20 0.52
MPO P05164 1/20 0.52
TSHR P16473 1/20 0.52
CYP1A2 P05177 2/20 0.51
PKM P14618 2/20 0.50
ALPI P09923 1/20 0.50
PTGS1 P23219 1/20 0.50
XIAP P98170 1/20 0.50
SLC7A5 Q01650 1/20 0.50
ALDH1A1 P00352 2/20 0.48
RECQL P46063 2/20 0.48
NOS3 P29474 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503050 1.00 LOXL2 (0.53) LOXL2MAPTKDM4EMEN1LMNA
SCHEMBL29556980 1.00 LOXL2 (0.53) LOXL2MAPTKDM4EMEN1LMNA
SCHEMBL1662034 1.00 LOXL2 (0.53) LOXL2MAPTKDM4EMEN1LMNA
SCHEMBL15921852 0.89 KDM4E (0.48) MAPTKDM4EMEN1LMNABLM
SCHEMBL15921853 0.89 KDM4E (0.48) MAPTKDM4EMEN1LMNABLM
SCHEMBL25357666 0.89 KDM4E (0.48) MAPTKDM4EMEN1LMNABLM
SCHEMBL14945005 0.86 LOXL2 (0.51) LOXL2MAPTKDM4EMEN1LMNA
SCHEMBL22190011 0.86 GRIN3B (0.46) LOXL2MAPTKDM4EMEN1LMNA
SCHEMBL22190009 0.86 GRIN3B (0.46) LOXL2MAPTKDM4EMEN1LMNA
SCHEMBL6495560 0.82 LOXL2 (0.47) LOXL2MAPTKDM4ECYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 WO claimed
WO-2025094171-A1 SUPERHYDROPHOBIC COATING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2025-05-08 WO claimed
EP-4401555-A1 ANTIMICROBIAL PEPTIDES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2024-07-24 EP claimed
WO-2023042201-A1 ANTIMICROBIAL PEPTIDES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-03-23 WO claimed
CN-114805487-A Polypeptide compound and application thereof 成都诺和晟泰生物科技有限公司 2022-07-29 CN claimed
CN-105143245-B Anti-scaling material 耶路撒冷希伯来大学伊森姆研究发展有限公司 2021-02-05 CN claimed
EP-2951195-B1 ANTIFOULING MATERIALS YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2020-02-19 EP claimed
EP-3374520-A1 BIOSENSORS Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2018-09-19 EP claimed
EP-3178836-A1 GADD45BETA TARGETING AGENTS Imperial Innovations Limited (GB) 2017-06-14 EP claimed
WO-2017081684-A1 BIOSENSORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2017-05-18 WO claimed
US-9631100-B2 Antifouling materials YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2017-04-25 US claimed
US-20150368294-A1 GADD45BETA TARGETING AGENTS IP2IPO INNOVATIONS LIMITED (GB) 2015-12-24 US claimed
US-20150368480-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2015-12-24 US claimed
EP-2951195-A1 ANTIFOULING MATERIALS Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) 2015-12-09 EP claimed
WO-2014118779-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-08-07 WO claimed
US-20120277164-A1 GADD45BETA TARGETING AGENTS IMPERIAL INNOVATIONS LIMITED (GB) 2012-11-01 US claimed
EP-2491051-A2 GADD45BETA TARGETING AGENTS Imperial Innovations Limited (GB) 2012-08-29 EP claimed
WO-2011048390-A2 GADD45BETA TARGETING AGENTS IMPERIAL INNOVATIONS LIMITED (GB) 2011-04-28 WO claimed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 US disclosed
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368294-A1 GADD45BETA TARGETING AGENTS DDB1, CCL2, DDIT3 LOXL2 2523/4885MAPT 3248/4885KDM4E 4430/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 LOXL2 1784/4885MAPT 4078/4885KDM4E 3531/4885
US-20120277164-A1 GADD45BETA TARGETING AGENTS DDB1, CCL2, DDIT3 LOXL2 2523/4885MAPT 3248/4885KDM4E 4430/4885
US-20150368480-A1 ANTIFOULING MATERIALS PFAS, FLNB, FLNA LOXL2 1216/4885MAPT 4276/4885KDM4E 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.